New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT03905148

Completed Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The trial is now complete, and results will help decide if further studies are warranted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer endometrial cancer malignant pancreatic neoplasm melanoma non-small cell lung carcinoma ovarian cancer thyroid cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

Blacktown Cancer and Haematology Centre

Blacktown, New South Wales, 2148, Australia
Linear Clinical Research

Nedlands, Western Australia, 6009, Australia
MD Anderson

Houston, Texas, 77030, United States
Peter MacCallum Cancer Centre

Melbourne, Victoria, 3000, Australia
The Prince of Wales Private Hospital - Specialist Medical Randwick

Randwick, New South Wales, 2031, Australia
University of California Los Angeles

Santa Monica, California, 90404, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.